Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer
Genmab reported updated Phase 2 data for petosemtamab plus FOLFOX/FOLFIRI in metastatic colorectal cancer, with confirmed/unconfirmed ORRs of 75% in first-line and 67% in second-line patients. Responses deepened with longer follow-up — ORR reached 81% in 1L left-sided tumors, disease control rates were 95% (1L) and 93% (2L), and most previously unconfirmed responses were subsequently confirmed. Safety was manageable, with discontinuations due to TEAEs in only 5% and 3% of patients. The data reinforce the ongoing global Phase 3 LiGeR trials in mCRC and HNSCC, and Genmab will host an investor update on October 28 at 5:00 p.m.
Key figures
- Drug Name
- petosemtamab (GEN1158)
- Phase Of Trial
- Phase 2
- Orr 1l
- 75%
- Orr 2l
- 67%
- Patients treated
- 79
- Orr 1l left sided
- 81%
- Disease control rate 1l
- 95%
- Disease control rate 2l
- 93%
- Median followup 1l months
- 5.9
- Median followup 2l months
- 7.1
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.